Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry ; volume:10 ; number:4 ; day:22 ; month:6 ; year:2023 ; pages:1055-1072 ; date:8.2023
Rheumatology and therapy ; 10, Heft 4 (22.6.2023), 1055-1072, 8.2023
- Creator
-
Curtis, Jeffrey R.
Yun, Huifeng
Chen, Lang
Ford, Stephanie S.
Hoogstraten, Hubert van
Fiore, Stefano
Ford, Kerri
Praestgaard, Amy
Rehberg, Markus
Choy, Ernest
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40744-023-00568-8
- URN
-
urn:nbn:de:101:1-2023100509052507209138
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Curtis, Jeffrey R.
- Yun, Huifeng
- Chen, Lang
- Ford, Stephanie S.
- Hoogstraten, Hubert van
- Fiore, Stefano
- Ford, Kerri
- Praestgaard, Amy
- Rehberg, Markus
- Choy, Ernest
- SpringerLink (Online service)
Other Objects (12)
Correction: Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry
Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry
Real-World Use and Effectiveness Outcomes in Patients with Rheumatoid Arthritis Treated with Upadacitinib: An Analysis from the CorEvitas Registry
Detection of novel drug-adverse drug reaction signals in rheumatoid arthritis and ankylosing spondylitis: analysis of Korean real-world biologics registry data
A Real-World Rheumatology Registry and Research Consortium: The German RheumaDatenRhePort (RHADAR) Registry
Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry
Malignancy validation in a United States registry of rheumatoid arthritis patients
Real-world retention rates of biologics in patients with rheumatoid arthritis
Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
Racial and ethnic disparities in a real-world precision oncology data registry
Late-onset rheumatoid arthritis registry study, LORIS study: study protocol and design
Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry
Correction: Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry
Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry
Real-World Use and Effectiveness Outcomes in Patients with Rheumatoid Arthritis Treated with Upadacitinib: An Analysis from the CorEvitas Registry
Detection of novel drug-adverse drug reaction signals in rheumatoid arthritis and ankylosing spondylitis: analysis of Korean real-world biologics registry data
A Real-World Rheumatology Registry and Research Consortium: The German RheumaDatenRhePort (RHADAR) Registry
Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry
Malignancy validation in a United States registry of rheumatoid arthritis patients
Real-world retention rates of biologics in patients with rheumatoid arthritis
Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
Racial and ethnic disparities in a real-world precision oncology data registry
Late-onset rheumatoid arthritis registry study, LORIS study: study protocol and design
Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry
Correction: Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry
Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry
Real-World Use and Effectiveness Outcomes in Patients with Rheumatoid Arthritis Treated with Upadacitinib: An Analysis from the CorEvitas Registry
Detection of novel drug-adverse drug reaction signals in rheumatoid arthritis and ankylosing spondylitis: analysis of Korean real-world biologics registry data
A Real-World Rheumatology Registry and Research Consortium: The German RheumaDatenRhePort (RHADAR) Registry
Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry
Malignancy validation in a United States registry of rheumatoid arthritis patients
Real-world retention rates of biologics in patients with rheumatoid arthritis
Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
Racial and ethnic disparities in a real-world precision oncology data registry
Late-onset rheumatoid arthritis registry study, LORIS study: study protocol and design